Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;14(3):437-440.
doi: 10.4103/1673-5374.245463.

Multitarget therapeutic strategies for Alzheimer's disease

Mostafa M Ibrahim  1 , Moustafa T Gabr  2
Affiliations
Review

Multitarget therapeutic strategies for Alzheimer's disease

Mostafa M Ibrahim et al. Neural Regen Res. 2019 Mar.

Abstract

Neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's diseases have multifaceted nature because of the different factors contributing to their progression. The complex nature of neurodegenerative diseases has developed a pressing need to design multitarget-directed ligands to address the complementary pathways involved in these diseases. The major enzyme targets for development of therapeutics for Alzheimer's disease are cholinesterase and β-secretase enzymes. In this review, we discuss recent advances in profiling single target inhibitors based on these enzymes to multitarget-directed ligands as potential therapeutics for this devastating disease. In addition, therapeutics based on iron chelation strategy are discussed as well.

Keywords: Alzheimer's disease; acetylcholinesterase; brain permeability; hybridization; multitarget-directed ligands; neurodegenerative diseases; tacrine; β-secretase.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
The multifactorial and complex nature of neurodegenerative diseases. ROS: Reactive oxygen species.
Figure 2
Figure 2
Chemical structures of compounds 1–3.
See this image and copyright information in PMC

References

    1. Costanzo P, Cariati L, Desiderio D, Sgammato R, Lamberti A, Arcone R, Salerno R, Nardi M, Masullo M, Oliverio M. Design, synthesis, and evaluation of donepezil-like compounds as AChE and BACE-1 inhibitors. ACS Med Chem Lett. 2016;7:470–475. - PMC - PubMed
    1. Di Martino RM, De Simone A, Andrisano V, Bisignano P, Bisi A, Gobbi S, Rampa A, Fato R, Bergamini C, Perez DI, Martinez A, Bottegoni G, Cavalli A, Belluti F. Versatility of the curcumin scaffold: discovery of potent and balanced dual BACE-1 and GSK-3beta inhibitors. J Med Chem. 2016;59:531–544. - PubMed
    1. Gabr MT, Abdel-Raziq MS. Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors. Bioorg Chem. 2018;80:245–252. - PubMed
    1. Hiremathad A, Piemontese L. Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer’s disease therapy. Neural Regen Res. 2017;12:1256–1261. - PMC - PubMed
    1. Hiremathad A, Keri RS, Esteves AR, Cardoso SM, Chaves S, Santos MA. Novel tacrine-hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer’s disease. Eur J Med Chem. 2018;148:255–267. - PubMed